Our US office is closed for Independence Day on 4 and 5 July 2022.

Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 302-062-1
Published by: London Business School
Published in: 2002
Length: 11 pages
Data source: Published sources

Abstract

This is the first of a two-case series (302-062-1 and 302-063-1). This case focuses on the formation of Roslin BioMed, a spin-off from the Roslin Institute that was formed to commercialise the nuclear transfer technology behind the successful cloning of Dolly the sheep. The case describes the background to the birth of Dolly, and then follows the subsequent events - the establishment of Roslin BioMed, the recruitment of Simon Best as Chief Executive of the company, and his discussions with various partner companies.
Location:
Industry:
Size:
Small-medium
Other setting(s):
1999

About

Abstract

This is the first of a two-case series (302-062-1 and 302-063-1). This case focuses on the formation of Roslin BioMed, a spin-off from the Roslin Institute that was formed to commercialise the nuclear transfer technology behind the successful cloning of Dolly the sheep. The case describes the background to the birth of Dolly, and then follows the subsequent events - the establishment of Roslin BioMed, the recruitment of Simon Best as Chief Executive of the company, and his discussions with various partner companies.

Settings

Location:
Industry:
Size:
Small-medium
Other setting(s):
1999

Related